MedTrace Logo

The Combination Therapy With Ra-223 and Enzalutamide

NCT03305224 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2021-09-09

No results posted yet for this study

Summary

This study is to evaluate preliminary efficacy of Ra-223 in combination with Enzalutamide in progressive CRPC patients with bone metastasis

Conditions

Interventions

DRUG

Ra-223 in combination with enzalutamide

Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day

Sponsors & Collaborators

  • Bayer Yakuhin, Ltd.

    collaborator INDUSTRY

  • Taro Iguchi, MD, PHD

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-27
Primary Completion
2021-10-30
Completion
2022-03-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03305224 on ClinicalTrials.gov